Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Arch Pediatr ; 28(8): 683-688, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34690027

ABSTRACT

BACKGROUND: Neonatal bacterial infections must be bacteriologically confirmed from laboratory samples to best adjust antibiotic therapy. Lumbar puncture (LP) has been recommended for infants younger than 1 month with suspected serious bacterial infection (SBI) to manage possible meningitis. However, the incidence of bacterial meningitis associated with other infections and particularly with urinary tract infections (UTIs) is low. Recourse to systematic LP may be less essential if infants have a UTI. We aimed (a) to determine the management and frequency of bacterial meningitis coexisting with a documented diagnosis of UTI in infants aged < 1 month who had an LP, and (b) to evaluate the management of infants in emergency admissions with suspected SBI while assessing antibiotic treatment. METHODS: We conducted a retrospective single-center study from January 2010 to April 2019 including all cases of neonatal bacterial infections, and collected data on the clinical, laboratory, and radiological features. RESULTS: In all, 409 infants were included in the study. Of these, 162 (39.6%) presented with a UTI and eight (2%) had bacterial meningitis. Of the infants diagnosed with UTI, 74.7% had an LP, of whom 34.7% experienced LP complications. No coexistence of UTI and bacterial meningitis was found among infants who had an LP and a documented UTI. CONCLUSION: Although not all infants had an LP and a urine culture at the same time, these results show that bacterial meningitis coexisting with a confirmed UTI diagnosis in infants is rare. Furthermore, LP can be traumatic in some cases and therefore its utility should be assessed according to the clinical context.


Subject(s)
Emergency Service, Hospital/standards , Spinal Puncture/standards , Urinary Tract Infections/diagnosis , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Disease Management , Emergency Service, Hospital/organization & administration , Emergency Service, Hospital/statistics & numerical data , Female , Humans , Infant , Infant, Newborn , Male , Retrospective Studies , Spinal Puncture/methods , Spinal Puncture/statistics & numerical data , Urinary Tract Infections/therapy
2.
J Hum Nutr Diet ; 32(4): 531-534, 2019 08.
Article in English | MEDLINE | ID: mdl-30916423

ABSTRACT

BACKGROUND: Monitoring activity-related energy expenditure (EE) is essential in the management of daily activity and the dietary programme in patients with type 2 diabetes (T2D) and must be estimated accurately. Accelerometry-based equations have frequently used to estimate EE, although the validity of these methods has not been confirmed in patients with T2D. The present study aimed to test the validity of an accelerometry-based method (Bouten's method) to assess EE during walking in patients with T2D. METHODS: The study included 20 patients with controlled T2D [mean (SD) duration: 10.6 (6.1) years; age: 57.5 (8.4) years; body mass index: 26.4 (2.6) kg m- ²]. All participants performed five 6-min periods of walking at different speeds (0.5-1.5 m s-1 ) on a treadmill. Mechanical data were recorded using an inertial measurement unit placed on the lower back with gas exchange being simultaneously monitored. RESULTS: Values of EE during walking estimated by the accelerometer method did not differ significantly from those measured by indirect calorimetry. Bias and root mean square error were -1.17 and 2.93 kJ min-1 , respectively, on average across speeds. CONCLUSIONS: Our results suggest that EE during walking may be accurately estimated in patients with diabetes mellitus using an accelerometer.


Subject(s)
Accelerometry/statistics & numerical data , Calorimetry, Indirect/statistics & numerical data , Diabetes Mellitus, Type 2/physiopathology , Energy Metabolism , Walk Test/statistics & numerical data , Accelerometry/methods , Aged , Female , Humans , Male , Middle Aged , Reproducibility of Results , Walk Test/methods , Walking
3.
J Oncol Pharm Pract ; 25(5): 1089-1098, 2019 Jul.
Article in English | MEDLINE | ID: mdl-29726786

ABSTRACT

PURPOSE: The aim of this study was to monitor environmental contamination by 10 antineoplastic drugs in Canadian oncology pharmacy and patient care areas. The secondary objective was to explore the impact of factors that may explain contamination. METHODS: Twelve standardized sites were sampled in each center (six in the pharmacy and six in patient care areas). Each sample was prepared to allow quantification of seven antineoplastic drugs (cyclophosphamide, ifosfamide, methotrexate, cytarabine, gemcitabine, 5-fluorouracil, irinotecan) by UPLC-MS-MS. Docetaxel, paclitaxel and vinorelbine were also detected, but not quantified due to sensibility limitations. The impact of some factors was evaluated compared with a Kolmogorov-Smirnov test for independent samples. RESULTS: Eighty-three Canadian centers were recruited in 2017. A total of 953 surfaces were sampled, 495 in pharmacy and 458 in patient care areas. Cyclophosphamide was most often found on surfaces (36% of samples positive, 75th percentile 0.0040 ng/cm2). The arm rest (81.7% of samples positive for at least one antineoplastic drug), the front grille inside the hood (78.3%) and the floor in front of the hood (61.4%) were more frequently contaminated. Centers who prepared more antineoplastic drugs per year had higher concentration on different surfaces ( p < 0.0001). CONCLUSION: Despite growing awareness and implementation of new safe handling guidelines, healthcare centers' surfaces remain contaminated with traces of many antineoplastic drugs. The use of personal protective equipment remains indisputable. Performing an annual monitoring remains a good indicator to monitor trends over time and to compare with similar centers.


Subject(s)
Antineoplastic Agents/analysis , Drug Contamination , Environmental Monitoring/methods , Canada , Chromatography, Liquid/methods , Equipment Contamination , Humans , Occupational Exposure/analysis , Pharmacies , Tandem Mass Spectrometry/methods
4.
J Occup Environ Hyg ; 14(8): 661-669, 2017 08.
Article in English | MEDLINE | ID: mdl-28574754

ABSTRACT

PURPOSE: Oncology workers are occupationally exposed to antineoplastic drugs. This exposure can induce adverse health effects. To reduce their exposure, contamination on surfaces should be kept as low as possible. The main objective of this study was to monitor environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in oncology pharmacy and patient care areas in Canadian centers. The secondary objective was to describe the impact of some factors that may limit contamination. METHODS: This is a descriptive study. Twelve standardized sites were sampled in each participating center (six in the pharmacy and six in patient care areas). Samples were analyzed for the presence of cyclophosphamide, ifosfamide, and methotrexate by ultra-performance liquid chromatography-tandem mass spectrometry technology. Descriptive statistical analyses were done and results were compared with a Kolmogorov-Smirnov test for independent samples. RESULTS: In 2016, 66 centers participated in this study (66/202, 32.7%). Overall, 43.4% (326/752) of the samples were positive for cyclophosphamide, 13.2% (99/752) for ifosfamide and 6.9% (52/752) for methotrexate. The 75th percentile value of cyclophosphamide surface concentration was 6.8 pg/cm2 and lower than the limit of detection for ifosfamide and methotrexate. Centers who prepared more antineoplastic drugs per year (p < 0.0001), who used more cyclophosphamide per year (p < 0.0001) and who primed antineoplastic IV tubing in patient care unit by nurses (p = 0.004) showed significantly higher surface contamination to cyclophosphamide. CONCLUSION: Environmental surveillance is one part of a comprehensive approach for minimizing hazardous exposures in healthcare. This study highlights a low level of contamination of three hazardous drugs amongst 66 Canadian centers. Regular environmental monitoring is a good practice to maintain contamination as low as reasonably achievable.


Subject(s)
Antineoplastic Agents/analysis , Cyclophosphamide/analysis , Environmental Monitoring/standards , Hospitals/statistics & numerical data , Ifosfamide/analysis , Methotrexate/analysis , Occupational Exposure/analysis , Canada , Equipment Contamination , Humans , Oncology Service, Hospital , Pharmacy Service, Hospital
6.
J Occup Environ Hyg ; 12(2): 87-94, 2015.
Article in English | MEDLINE | ID: mdl-25105559

ABSTRACT

No occupational exposure limit exists for antineoplastic drugs. The main objective of this study was to describe environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in pharmacy and patient care areas of Canadian hospitals in 2013. The secondary objective was to compare the 2013 environmental monitoring results with previous studies. Six standardized sites in the pharmacy and six sites on patient care areas were sampled in each participating center. Samples were analyzed for the presence of cyclophosphamide, ifosfamide, and methotrexate by UPLC-MSMS. The limit of detection (LOD) in pg/cm(2) was 1.8 for cyclophosphamide, 2.2 for ifosfamide, and 7.5 for methotrexate. The 75th percentile of cyclophosphamide concentration was compared between the 2013, 2008-2010, and 2012 studies. Thirty-six hospitals participated in the study and 422 samples were collected. Overall, 47% (198/422) of the samples were positive for cyclophosphamide, 18% (75/422) were positive for ifosfamide, and 3% (11/422) were positive for methotrexate. In 2013, the 75th percentile value of cyclophosphamide surface concentration was reduced to 8.4pg/cm(2) (n = 36), compared with 9.4pg/cm(2) in 2012 (n = 33) and 40pg/cm(2) (n = 25) in 2008-2010. The 75th percentile for ifosfamide and methotrexate concentration remained lower than the LOD. The 2013 study shows an improvement in the surface contamination level, and a plateau effect in the proportion of positive samples.


Subject(s)
Antineoplastic Agents/analysis , Environmental Monitoring , Environmental Pollutants/analysis , Hospitals , Pharmacy Service, Hospital , Cyclophosphamide/analysis , Drug Compounding/methods , Follow-Up Studies , Ifosfamide/analysis , Methotrexate/analysis , Occupational Exposure/analysis , Quebec
7.
Arch Pediatr ; 21(10): 1120-2, 2014 Oct.
Article in French | MEDLINE | ID: mdl-25125034

ABSTRACT

Lactic acidosis is a recognized event in adult patients with acute severe asthma (ASA). Only a few cases have been reported in children. Hereinafter is reported the case of a 2-year-old girl hospitalized in the pediatric intensive care unit for ASA, which was treated with high-flow oxygen therapy and intravenous methylprednisolone and salbutamol. During hospitalization, she had metabolic acidosis with a 7.29 pH, a 26mmHg hypocapnia, and a decrease in bicarbonates to 12 mmol/L. The anion gap was increased to 20 mmol/L and lactates to 8 mmol/L. The work-up for a congenital metabolic disease was normal. Progression was propitious with spontaneous improvement of lactic acidosis, and the child was discharged from the intensive care unit after 72 h. The origin of lactic acidosis during ASA seems to be multifactorial. Although its recovery can be spontaneous, it is important to know how to identify it because it can worsen respiratory symptoms and can lead to incongruous therapeutic escalation.


Subject(s)
Acidosis, Lactic/complications , Asthma/complications , Acidosis, Lactic/diagnosis , Asthma/therapy , Child, Preschool , Female , Humans , Hypocapnia/complications , Hypocapnia/diagnosis , Intensive Care Units, Pediatric , Severity of Illness Index
8.
Arch Pediatr ; 21(5): 497-500, 2014 May.
Article in French | MEDLINE | ID: mdl-24709317

ABSTRACT

Deep vein thrombosis occurs in 30% of patients with essential thrombocythemia, but rarely at initial diagnosis. We report two pediatric patients with essential thrombocythemia revealed by atypical deep vein thrombosis. First, a 16-year-old girl presented Budd-Chiari syndrome revealed by a hemorrhagic shock. Clinical exam revealed isolated splenomegaly. A search for thrombophilia found a factor V Leiden homozygous mutation and a Jak2 mutation. Bone marrow biopsy confirmed the diagnosis of a myeloproliferative disorder. The second case, a 17-year-old girl, had a routine examination by her physician that revealed splenomegaly. Ultrasonography displayed thrombus in the splenic and portal vein. An isolated Jak2 mutation was found and a myeloproliferative disorder was confirmed by bone marrow biopsy. The diagnosis of myeloproliferative disorder was made in both patients presenting atypical venous thrombosis with a Jak2 mutation and confirmed by bone marrow biopsy. These initial presentations of myeloproliferative disorders are rare in childhood and possibly underdiagnosed.


Subject(s)
Budd-Chiari Syndrome/etiology , Shock, Hemorrhagic/etiology , Thrombocytosis/diagnosis , Venous Thrombosis/etiology , Adolescent , Anticoagulants/therapeutic use , Biopsy , Bone Marrow/pathology , Budd-Chiari Syndrome/diagnosis , Budd-Chiari Syndrome/drug therapy , Budd-Chiari Syndrome/genetics , DNA Mutational Analysis , Diagnosis, Differential , Factor V/genetics , Female , Hematemesis/diagnosis , Hematemesis/etiology , Hematemesis/genetics , Homozygote , Humans , Janus Kinase 2/genetics , Shock, Hemorrhagic/diagnosis , Shock, Hemorrhagic/genetics , Thrombocytosis/drug therapy , Thrombocytosis/genetics , Ultrasonography , Venous Thrombosis/diagnosis , Venous Thrombosis/drug therapy , Venous Thrombosis/genetics
9.
Opt Lett ; 38(2): 127-9, 2013 Jan 15.
Article in English | MEDLINE | ID: mdl-23454937

ABSTRACT

We report the first demonstration of a Raman fiber laser (RFL) emitting in the mid-infrared, above 3 µm. The operation of a single-mode As2S3 chalcogenide glass based RFL at 3.34 µm is demonstrated by using a low-loss Fabry-Pérot cavity formed by a pair of fiber Bragg gratings. A specially designed quasi-cw erbium-doped fluoride fiber laser emitting at 3.005 µm is used to pump the RFL. A laser output peak power of 0.6 W is obtained with a lasing efficiency of 39% with respect to the launched pump power.

10.
Biol Reprod ; 78(4): 618-35, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18003951

ABSTRACT

Spermatozoa are terminally differentiated cells produced during the complex process of spermatogenesis. Although the role of their residual RNA content is still being debated, this transcriptome may represent a fingerprint of spermatogenesis quality. In the present study, we undertook differential transcript profiling of spermatozoa from fertile bulls with extreme nonreturn rates (NRRs): a low-fertile group, and a high-fertile group. Using the suppression-subtractive hybridization technique in combination with macroarray analysis, we also identified novel genes. Both extreme NRR index groups retained redundant identity, such as ribosomal and mitochondrial sequences, at a statistically significant level. An elevated number of 12S, 18S, and Large Chain R rRNA gene copies were found in low-fertile bulls and validated in spermatozoa by quantitative RT-PCR for a small cohort of bulls with known fertility index. Whereas the high-NRR library exhibited a large proportion (29%) of transcripts associated with known functions (e.g., metabolism, signal transduction, translation, glycosylation, and protein degradation), only 10% of the low-NRR sequences did. This difference is also conveyed by two other categories: 17% Bovine Genome and 48% unknown in the high-NRR library, compared with 3% and 80%, respectively, in the low-NRR library. Some of the unknown transcripts are similar to expressed sequence tags detected in the male reproductive organ of certain plants and retain homology to a putative human protein. Whereas the individual transcriptome profiles may be useful in fertility assessment, these findings also suggest cross-species conservation, could contribute to a better understanding of spermatogenesis, and provide new insights regarding idiopathic infertility.


Subject(s)
Cattle , Fertility/genetics , Gene Expression Profiling , Nucleic Acid Hybridization/methods , Semen/chemistry , Animals , Cattle Diseases/genetics , Gene Library , Infertility, Male/genetics , Infertility, Male/veterinary , Male , Oligonucleotide Array Sequence Analysis , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction
11.
Am J Physiol Regul Integr Comp Physiol ; 291(4): R977-86, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16675634

ABSTRACT

This study examined the role of intrarenal ANG II in the renal vascular reactivity changes occurring in the remaining kidney undergoing adaptation following contralateral nephrectomy. Renal blood flow responses to intrarenal injections of ANG II (0.25 to 5 ng) were measured in anesthetized euvolemic male Wistar rats 1, 4, 12, and 24 wk after uninephrectomy (UNX) or sham procedure (SHAM). At week 4, renal vasoconstriction induced by 2 ng ANG II was greater in UNX (69 +/- 5%) than in SHAM rats (50 +/- 3%; P < 0.01). This response was inhibited, by 50 and 66%, and by 20 and 25%, in SHAM and UNX rats, after combined injections of ANG II and losartan, or PD-123319 (P < 0.05), respectively. Characteristics of ANG II receptor binding in isolated preglomerular resistance vessels were similar in the two groups. After prostanoid inhibition with indomethacin, renal vasoconstriction was enhanced by 42 +/- 8% (P < 0.05), only in SHAM rats, whereas after 20-HETE inhibition with HET0016, it was reduced by 53 +/- 16% (P < 0.05), only in UNX rats. These differences vanished after concomitant prostanoid and 20-HETE inhibition in the two groups. After UNX, renal cortical protein expression of cytochrome P-450 2c23 isoform (CYP2c23) and cyclooxygenase-1 (COX-1) was unaltered, but it was decreased for CYP4a and increased for COX-2. In conclusion, renal vascular reactivity to ANG II was significantly increased in the postuninephrectomy adapted kidney, independently of protein expression, but presumably involving interactions between 20-HETE and COX in the renal microvasculature and changes in the paracrine activity of ANG II and 20-HETE.


Subject(s)
Angiotensin II/pharmacology , Hydroxyeicosatetraenoic Acids/metabolism , Renal Circulation/drug effects , Renal Circulation/physiology , Vasoconstrictor Agents/pharmacology , Adaptation, Physiological/physiology , Amidines/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Cyclooxygenase 1/metabolism , Cyclooxygenase Inhibitors/pharmacology , Cytochrome P-450 CYP2J2 , Cytochrome P-450 Enzyme System/metabolism , Dinoprostone/urine , Hydroxyeicosatetraenoic Acids/antagonists & inhibitors , Imidazoles/pharmacology , Indomethacin/pharmacology , Losartan/pharmacology , Male , Microcirculation/drug effects , Microcirculation/physiology , Nephrectomy , Norepinephrine/pharmacology , Pyridines/pharmacology , Rats , Rats, Wistar , Vasoconstriction/drug effects , Vasoconstriction/physiology
12.
Appl Opt ; 45(15): 3495-500, 2006 May 20.
Article in English | MEDLINE | ID: mdl-16708094

ABSTRACT

A magnetic liquid mirror based on ferrofluids was demonstrated. Magnetic liquid mirrors represent a major departure from solid mirror technology. They present both advantages and disadvantages with respect to established technologies. Stroke (from a fraction of a wave to several hundreds of micrometers), cost (a few dollars per actuator), and scalability (hundreds of thousands of actuators) are the main advantages. Very large mirrors having diameters of the order of a meter should be feasible. There are a few disadvantages. The most important disadvantage is the time response, which is of the order of a few milliseconds. Although this time response could be further decreased with additional technical developments, it is unlikely to match the speed of solid mirrors. The technology is still in its infancy, and considerable work must still be done. However, the advantages are such that the technology is worth pursuing.

13.
World J Surg ; 30(5): 833-40, 2006 May.
Article in English | MEDLINE | ID: mdl-16555024

ABSTRACT

BACKGROUND: There is ongoing controversy as to the indications for and extent of lateral cervical lymphadenectomy for patients with papillary thyroid cancer (PTC). While most now agree that prophylactic lymph node dissections (LND) play no role, at the University of California, San Francisco (UCSF) we limit LND selectively on a level by level basis, and resect only the levels thought to harbor disease or to be at increased risk of metastases. This initial 'selective LND' usually includes levels III and IV (due to the well-documented increased likelihood of metastases to these levels) and levels I, II, and V are included when there is clinical or radiological evidence of disease or increased risk of it. METHODS: A retrospective review of the clinical charts and hospital records of 106 consecutive patients who had metastatic PTC and who underwent at least one lateral cervical LND at UCSF between January 1995 and December 2003 was carried out. Data were collected to assess which patients had levels I, II, and/or V included in their initial ipsilateral and/or contralateral LND and to determine the recurrence rates at these levels if they had previously been excised compared with if they had not. Chi-squared and Fisher exact tests were utilized for statistical comparison, where appropriate. RESULTS: A total of 140 initial lateral LND were performed: 104 ipsilateral and 36 contralateral. In these initial LND, 3.9%, 72.5%, and 18.6% of patients had levels I, II, and V resected on the ipsilateral side, and 2.9%, 60.0%, and 37.1% of patients had levels I, II, and V resected on the contralateral side. Recurrence at levels I and V was uncommon in all patient populations. Recurrence at level II was 19% ipsilaterally and 10% contralaterally when the level was previously resected and 21% ipsilaterally and 14% contralaterally when the level was not previously resected. There was no statistically significant difference in recurrence at level II when the level had previously been resected compared with when it had not. CONCLUSIONS: If utilized in the appropriate patient population, a selective approach to lateral cervical LND for PTC can be a successful alternative to the routine modified radical LND. Levels I and V do not require resection unless there is clinical or radiological evidence of disease. Guidelines for which patients may be considered for this less aggressive approach to level II nodal metastases are suggested.


Subject(s)
Adenocarcinoma, Papillary/pathology , Neck Dissection/methods , Thyroid Neoplasms/pathology , Adenocarcinoma, Papillary/surgery , Adult , Female , Humans , Lymphatic Metastasis , Male , Neoplasm Recurrence, Local , Retrospective Studies , Thyroid Neoplasms/surgery , Thyroidectomy
14.
Clin Exp Pharmacol Physiol ; 31(10): 683-90, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15554908

ABSTRACT

A significant renal vasodilation was observed previously after an acute cyclo-oxygenase (COX) inhibition induced with indomethacin. Because this effect could be due to COX-dependent intrarenal metabolization of arachidonic acid through cytochrome P450 (CYP450) pathways, the aim of the present study was to investigate, in vivo, possible interactions between COX and CYP450 mono-oxygenases. Mean arterial pressure (MAP) and renal blood flow (RBF), using an electromagnetic flow transducer for RBF evaluation, were measured continuously in 71 anaesthetized euvolaemic rats. Appropriate solvents (vehicle), 3 mg/kg indomethacin, 17-octadecynoic acid (17-ODYA; 2 mmol/L), either miconazole (MI; 1.5 mmol/L) or N-methylsulphonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH; 5 mg/kg) and N'-hydroxyphenylformamidine (HET0016; 5 or 10 mg/kg) were administered to inhibit either COX, CYP450 mono-oxygenases, epoxygenases or hydroxylase, respectively. The CYP450 and COX inhibitors were also combined as follows: 17-ODYA/indomethacin, MI (or MS-PPOH)/indomethacin, HET0016/indomethacin and indomethacin/HET0016. Mean arterial pressure and RBF were not modified by vehicle, 17-ODYA or MI (or MS-PPOH). However, MAP decreased slightly (P < 0.05; paired t-test, 5 d.f.) and RBF increased transiently (P < 0.05; anova, 5 d.f.) after HET0016. In contrast, MAP decreased by 10 mmHg (P < 0.05) and RBF increased by 10% (P < 0.05) after indomethacin. This enhancement was prevented by 17-ODYA or MI (or MS-PPOH), but not by HET0016. Moreover, RBF increased step-wise to 21% in the indomethacin/HET0016 experiment (P < 0.05). Consequently, changes from baseline in renal vascular resistance differed among treatments, averaging -2 +/- 3 (vehicle), -13 +/- 3 (indomethacin; P < 0.05 vs vehicle), -4 +/- 3 (17-ODYA/indomethacin), -3 +/- 4 (MI or MS-PPOH/indomethacin), -15 +/- 3 (HET0016/indomethacin; P < 0.05) and -22 +/- 4% (indomethacin/HET0016; P < 0.05). In conclusion, these results demonstrate that the renal vasodilation induced by indomethacin can be prevented by prior inhibition of CYP450 mono-oxygenases and further suggest that the CYP450 epoxygenases pathway may prevail.


Subject(s)
Arachidonic Acid/metabolism , Cyclooxygenase Inhibitors/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Indomethacin/pharmacology , Renal Circulation/drug effects , Animals , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Fatty Acids, Unsaturated/pharmacology , Hemodynamics/drug effects , Hydroxyeicosatetraenoic Acids/metabolism , Kidney/drug effects , Kidney/physiology , Male , Miconazole/pharmacokinetics , Rats , Rats, Wistar , Vasodilation/drug effects , Vasodilation/physiology
16.
Cell Transplant ; 12(1): 91-100, 2003.
Article in English | MEDLINE | ID: mdl-12693669

ABSTRACT

Migration of transplanted myogenic cells occurs during both embryogenesis and regeneration of skeletal muscles and is important for successful myoblast transplantation, but little is known about factors that promote chemotaxis of these cells. Tumor necrosis factor-alpha (TNF-alpha) is known to induce chemotactic effect on several cell types. In this study, we investigated its influence on the in vitro and in vivo motility of C2C12 and primary myoblasts. In the in vitro test performed in the blind-well Boyden chambers, we showed that TNF-alpha (50-400 U/ml) significantly enhanced the ability of myogenic cells to migrate. The dose-response curve for this factor was bell shaped, with maximum activity in the 200 U/ml range. In the in vivo test, intramuscular administration of TNF-alpha was performed by an Alzet pump connected to a perforated polyethylene microtube inserted in the tibialis anterior (TA) of CD1 mice. In these experiments, myoblasts were injected under the muscle epimysium. The recipient mice were immunosuppressed with FK506. Our results showed that, 5 days after myoblast transplantation, cells migrated further in the muscles infused with TNF-alpha than in the muscles not exposed to TNF-alpha. TNF-alpha not only has a chemotactic activity but may also modify cell migration via its action on matrix metalloproteinase (MMP) expression. The proteolytic activities of the MMPs secreted in the muscles were thus also assessed by gelatin zymography. The results showed an increased of MMP-2 and MMP-9 transcripts in the TNF-alpha-infused muscles injected with myogenic cells. Myoblast migration during transplantation may be enhanced by overlapping gradients of several effector molecules such as TNF-alpha, interferon-gamma (INF-gamma), and interleukins, released at the site of muscle injury. We propose that TNF-alpha may promote myoblast migration directly through chemotactic activity and indirectly by enhancing MMP activity at the site of muscle injury.


Subject(s)
Cell Differentiation/physiology , Chemotaxis/physiology , Muscle, Skeletal/metabolism , Muscular Diseases/therapy , Myoblasts/transplantation , Tissue Transplantation/methods , Tumor Necrosis Factor-alpha/metabolism , Animals , Cell Differentiation/drug effects , Cells, Cultured , Chemotaxis/drug effects , Cytokines/immunology , Cytokines/metabolism , Dose-Response Relationship, Drug , Immunosuppressive Agents/pharmacology , Lymphocyte Function-Associated Antigen-1/drug effects , Lymphocyte Function-Associated Antigen-1/metabolism , Macrophage-1 Antigen/drug effects , Macrophage-1 Antigen/metabolism , Matrix Metalloproteinases/drug effects , Matrix Metalloproteinases/metabolism , Mice , Mice, Transgenic , Muscle, Skeletal/drug effects , Muscle, Skeletal/injuries , Myoblasts/drug effects , Myoblasts/metabolism , Treatment Outcome , Tumor Necrosis Factor-alpha/pharmacology
17.
Am J Physiol Renal Physiol ; 281(6): F1132-40, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11704565

ABSTRACT

Renal blood flow (RBF) autoregulatory efficiency may be enhanced during NO inhibition in the rat, as recently reported. Under these conditions, endothelin (ET) synthesis and release may be increased. Our purpose was therefore to determine the role of ET in RBF autoregulatory changes induced by NO inhibition. To address this point, ET(A/B) receptors were blocked in anesthetized rats with bosentan, or selectively with BQ-610 or BQ-788. NO synthesis was inhibited with N(G)-nitro-L-arginine methyl ester (L-NAME). Mean arterial pressure (MAP) was decreased after bosentan (-10 mmHg; P < 0.01) or increased after L-NAME (25 mmHg; P < 0.001). RBF measured with an electromagnetic flow probe was reduced by L-NAME (-50%) and by BQ-788 (-24%). The pressure limits of the autoregulatory plateau (P(A) approximately 100 mmHg) and of no RBF autoregulation (P(o) approximately 80 mmHg) were significantly lowered by 15 mmHg after L-NAME but were unchanged after bosentan, BQ-610, or BQ-788. During NO inhibition, autoregulatory resetting was completely hindered by bosentan (P(A) approximately 100 mmHg) and by ET(B) receptor blockade with BQ-788 (P(A) approximately 106 mmHg), but not by ET(A) receptor blockade with BQ-610 (P(A) approximately 85 mmHg). These results suggest that the involvement of ET in the RBF autoregulatory resetting occurs during NO inhibition, possibly by preferential activation of the ET(B) receptor. However, the relative contribution of ET receptor subtypes remains to be further specified.


Subject(s)
Endothelins/physiology , Kidney/blood supply , Nitric Oxide/antagonists & inhibitors , Renal Circulation , Angiotensin Receptor Antagonists , Animals , Blood Pressure/drug effects , Bosentan , Endothelin Receptor Antagonists , Enzyme Inhibitors , Homeostasis , Kidney/physiology , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Oligopeptides/pharmacology , Piperidines/pharmacology , Rats , Rats, Wistar , Receptor, Angiotensin, Type 1 , Regional Blood Flow/drug effects , Renal Circulation/drug effects , Sulfonamides/pharmacology , Vascular Resistance
18.
Transplantation ; 72(1): 38-44, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11468532

ABSTRACT

BACKGROUND: Overcoming adverse effects of immunosuppressors can be achieved by combining different drugs, thus allowing a dosage reduction. Myoblast transplantation is a potential therapy for Duchenne muscular dystrophy. Our research group previously established that FK506 (tacrolimus) is an effective immunosuppressive drug for myoblast transplantation in mice and monkeys. METHODS: In the present study, a reduced dose of FK506 at 1.0 mg/kg/day was used in combination with mycophenolate mofetil (MMF; 80 mg/kg/day) as an immunosuppressive protocol for myoblast transplantation. Graft success was evaluated by quantifying the number of dystrophin-positive fibers per muscle section that were injected with normal cells. RESULTS: MMF used alone could not prevent immune rejection of the transplanted myoblasts. MMF given in combination with FK506 immediately after transplantation reduced the success of myoblast transplantation by about 50%. A low dose of FK506 combined with MMF after the establishment of the graft (3 weeks) maintained graft success and controlled immune infiltration compared with a low dose of FK506 alone. However, lymphocyte infiltration was observed at longer term using a low dose of FK506 combined with MMF. CONCLUSIONS: The diminution of graft success when combining FK506 and MMF by the time of myoblast transplantation could be attributed to the inhibition of myoblast fusion by MMF. The use of MMF and FK506 after the establishment of the graft did not reduce graft success, however, this combination was not effective at controlling long-term immune rejection in comparison with the optimal dose of FK506 alone.


Subject(s)
Cell Transplantation , Immunosuppressive Agents/therapeutic use , Muscle, Skeletal/cytology , Mycophenolic Acid/therapeutic use , Tacrolimus/therapeutic use , Animals , Cell Division/drug effects , Cell Fusion , Cells, Cultured , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Graft Rejection/prevention & control , Graft Survival/drug effects , Immune System/pathology , Immunosuppressive Agents/administration & dosage , Mice , Mice, Inbred Strains , Mice, Inbred mdx , Mice, Transgenic , Muscle, Skeletal/pathology , Mycophenolic Acid/analogs & derivatives , Tacrolimus/administration & dosage
19.
J Cell Biol ; 152(2): 335-48, 2001 Jan 22.
Article in English | MEDLINE | ID: mdl-11266450

ABSTRACT

Duchenne muscular dystrophy is a lethal recessive disease characterized by widespread muscle damage throughout the body. This increases the difficulty of cell or gene therapy based on direct injections into muscles. One way to circumvent this obstacle would be to use circulating cells capable of homing to the sites of lesions. Here, we showed that stem cell antigen 1 (Sca-1), CD34 double-positive cells purified from the muscle tissues of newborn mice are multipotent in vitro and can undergo both myogenic and multimyeloid differentiation. These muscle-derived stem cells were isolated from newborn mice expressing the LacZ gene under the control of the muscle-specific desmin or troponin I promoter and injected into arterial circulation of the hindlimb of mdx mice. The ability of these cells to interact and firmly adhere to endothelium in mdx muscles microcirculation was demonstrated by intravital microscopy after an intraarterial injection. Donor Sca-1, CD34 muscle-derived stem cells were able to migrate from the circulation into host muscle tissues. Histochemical analysis showed colocalization of LacZ and dystrophin expression in all muscles of the injected hindlimb in all of five out of five 8-wk-old treated mdx mice. Their participation in the formation of muscle fibers was significantly increased by muscle damage done 48 h after their intraarterial injection, as indicated by the presence of 12% beta-galactosidase-positive fibers in muscle cross sections. Normal dystrophin transcripts detected enzymes in the muscles of the hind limb injected intraarterially by the mdx reverse transcription polymerase chain reaction method, which differentiates between normal and mdx message. Our results showed that the muscle-derived stem cells first attach to the capillaries of the muscles and then participate in regeneration after muscle damage.


Subject(s)
Cell Transplantation/methods , Dystrophin/genetics , Hematopoietic Stem Cells/physiology , Muscle, Skeletal/cytology , Muscular Dystrophy, Animal/therapy , Actins/analysis , Animals , Animals, Newborn , Antigens, CD34/analysis , Antigens, Ly/analysis , Cell Adhesion , Cell Differentiation , Cell Line , Dystrophin/analysis , Endothelium, Vascular/physiology , Genetic Therapy , Hematopoietic Stem Cells/cytology , Hindlimb , Immunophenotyping , Injections, Intra-Arterial , Membrane Proteins/analysis , Mice , Mice, Inbred mdx , Mice, Transgenic , Microcirculation/physiology , Muscle Fibers, Skeletal/cytology , Muscle Fibers, Skeletal/physiology , Myosins/analysis , Transcription, Genetic , beta-Galactosidase/analysis , beta-Galactosidase/genetics
20.
Mol Ther ; 3(3): 310-8, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11273772

ABSTRACT

The Tat protein from HIV-1, when fused with heterologous proteins or peptides, can traverse biological membranes in a process called "protein transduction," delivering its cargo into cells. A Tat-eGFP fusion protein was purified from bacteria to study the transduction kinetics of Tat fusion proteins into cultured myoblasts and in the muscle tissue. Correctly folded Tat-eGFP reaches a maximum intracellular level in nearly 30 min, while its endogenous fluorescence is first detected only after 14 h. The nuclear localization signal from the basic domain of Tat was not sufficient to confer nuclear localization to Tat-eGFP, suggesting that the nuclear import pathway used by the exogenously added Tat-eGFP might be sensitive to the folding state of eGFP. In mice, the direct delivery to the muscle tissue using subcutaneous injections or the intra-arterial pathway led to few positive fibers in the muscle periphery or surrounding the blood vessels. Muscles injected with Tat-eGFP showed intense labeling of the extracellular matrix (ECM), suggesting that, although Tat fusion proteins can transduce muscle fibers, their binding by components of the ECM surrounding myofibers could interfere with the intracellular transduction process.


Subject(s)
Gene Products, tat/metabolism , HIV-1 , Muscle, Skeletal/metabolism , Animals , Antimicrobial Cationic Peptides , Biological Transport , Cells, Cultured , Gene Products, tat/genetics , Gene Transfer Techniques , Green Fluorescent Proteins , Humans , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Mice , Mice, Inbred BALB C , Recombinant Fusion Proteins/administration & dosage , Transcriptional Activation , Transduction, Genetic , Transfection , tat Gene Products, Human Immunodeficiency Virus
SELECTION OF CITATIONS
SEARCH DETAIL
...